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Squamous cell carcinomas of the head and neck are the subject of numerous current
studies, especially in view of the increasing incidence of tumors induced by human
papillomavirus (HPV) and the latest changes to the TNM classification of oropharyngeal
squamous cell carcinoma (OPSCC). In addition to HPV status, the presence of extranodal
extension of lymph node metastases represents an important risk and prognostic
factor, which has now been integrated into the staging algorithm of the eighth edition
of TNM classification for HPV-negative OPSCC. In the past numerous studies had
shown a lack of prognostic significance of extranodal extension in HPV-associated
tumors. However, extranodal extension–as a possible risk factor even in HPV-positive
OPSCC–remains an important subject of current studies, which are now particularly
characterized by high numbers of cases. In this paper, diagnostic methods and the
prognostic significance of extranodal extension in surgically treated HPV-positive OPSCC
are presented and discussed based on relevant literature, and the results of current
publications are summarized. Further development of diagnostic criteria and procedures
as well as international standardization of clinical diagnostics of extranodal extension
should be encouraged. Several studies demonstrate that extranodal extension results in
worse survival outcomes even in HPV-positive tumors, in contrast to results of previous
studies. Consequently, whether the prognostic significance of extranodal extension is not
actually relevant to outcome and the staging algorithm of HPV-positive OPSCC should
be questioned and further analyzed.
Keywords: extranodal extension, TNM classification, human papilloma virus, oropharyngeal carcinoma, HPV,
OPSCC
INTRODUCTION
The role of HPV in OPSCC has gained a great deal of attention in recent years. In
addition to its causative role, HPV infection also proved to have a clear prognostic
value (1). With the introduction of the eighth edition of the TNM classification (2017)
a distinction is being made for the first time between HPV-positive and HPV-negative
squamous cell carcinomas by the use of p16 immunohistochemistry (p16 IHC) as part
of the staging of oropharyngeal squamous cell carcinoma (OPSCC). Furthermore, the
prognostic influence of extranodal extension (ENE) of lymph node metastases for HPV-negative
OPSCC was integrated into the staging algorithm. The prognostic influence of ENE
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has been analyzed in several studies and it was recognized
as an essential prognostic factor, which should facilitate an
even more accurate estimate of the risk of regional disease
recurrences or distant metastases (1, 2). In the clinical staging
of lymph node metastasis, defined criteria must be fulfilled
for the diagnosis of clinical ENE. According to the new
edition of the TNM classification, ENE in p16-positive OPSCC
compared to HPV-negative tumors does not result in prognostic
upstaging with regard to the N category or UICC stage. Several
current studies focus on evaluating extensively the prognostic
influence of ENE in HPV-positive tumors. The diagnostic
methods and significance of ENE—with particular attention
to surgically treated HPV-positive OPSCC—are presented and
discussed below.
DEFINITION OF EXTRANODAL EXTENSION
Extranodal extension was first described in 1930 by Rupert A.
Willis in the context of autopsies on patients with advanced
head and neck squamous cell carcinoma (HNSCC) (1, 3). It is
generally defined as the spread of tumor tissue or neoplastic cells
outside the lymph node capsule with infiltration of perinodal
soft tissue (4). By means of histopathologic examination (lymph
node metastasis without ENE; Figure 1A), ENE can additionally
be subdivided into the categories “microscopic” (≤2mm beyond
the lymph node capsule; Figure 1B) and “macroscopic” (>2mm
beyond the lymph node capsule; Figure 1C) (4). For instance,
Bauer et al. in their 2019 study illustrated the importance of
the extent of ENE in patients with OPSCC (5). Patients were
classified into the categories ENE-negative, microscopic ENE,
and macroscopic ENE, and patients with microscopic ENE
showed significantly reduced survival compared to patients with
negative ENE status (hazard ratio = HR = 1.52; 95% CI = 1.00–
2.31; p = 0.048) (5). Patients with macroscopic ENE had the
worst outcome (HR = 2.50; 95% CI = 1.39–4.51; p = 0.002)
(5). In addition to that, recent data even differentiate between
the categories “no ENE,” “minimal ENE” (≤1mm beyond the
lymph node capsule”), and “>1mm beyond the lymph node
capsule” (6).
Although these subcategories have not yet been applied for
the purpose of pN classification, they are recommended by
the AJCC for data collection and analyses and find application
in recent studies (4). In addition to patients with diagnosed
lymph node metastases and ENE of metastases, it is reported
that a proportion of 10.5–25% of patients exhibit microscopic
ENE despite having a clinically unremarkable lymph node status
(1, 7). Thus, microscopic ENE, micrometastases, or soft tissue
deposits can cause an underestimate of the incidence of ENE—
especially with regard to patients with primary radiotherapy that
are classified within the cTNM-classification system (1, 7).
IMAGING AND CLINICAL PREDICTORS IN
DIAGNOSING EXTRANODAL EXTENSION
In addition to the widely used diagnostic methods involved
in postoperative histopathologic examination, various imaging
techniques can be applied, such as ultrasound, magnetic
resonance imaging (MRI), and computed tomography (CT).
Clinical diagnosis of ENE of lymph node metastases presupposes
that clear, defined criteria are met (8). Clinical or radiologic signs
of tumor invasion alone (including the skin and surrounding
soft tissue) as well as clinical symptoms of neural involvement
(e.g., paresis of cranial nerves) are defined as clinical ENE
in the new TNM classification (9). The following criteria are
used for radiologic diagnosis of ENE for both CT and MRI:
presence of irregular nodal capsular enhancement, loss of distinct
nodal margins and infiltration into adjacent structures (fatty
tissue, muscle, blood vessels) (1, 10, 11). Generally speaking,
however, the limited sensitivity and specificity of the methods
used in relation to the clinical diagnosis of ENE need to be
discussed (8). For example, Steinkamp et al. showed in several
publications a sensitivity of ∼80.9% with specificity of 72.2% for
CT investigations and sensitivity of ∼74.4% and specificity of
72.2% for MRI imaging (1, 12, 13). Clinical diagnosis of ENE by
ultrasound, with a sensitivity of 78.6% and specificity of 81.8%,
achieved slightly better results than CT or MRI (1, 14). With
regard to diagnosing ENE by contrast-enhanced CT imaging, the
values quoted in the literature according to Faraji et al. and others
range from 75 to 86% for the accuracy of predicting pathologic
ENE, from 65 to 90% for sensitivity and 73–91% for the specificity
of the imaging method (12, 15–21). As clinical diagnosis of
ENE, for example, does not differentiate between microscopic
and macroscopic ENE so far, the data of patient collectives with
primary surgery and collectives with primary radiotherapy are
not readily comparable.
For a long time there have been strong demands for
standardization and further development of investigation
methods and internationally recognized diagnostic criteria for
the imaging modalities of ultrasound, CT and MRI (1). Only
recently Kann et al. published their study on the diagnosis
of lymph node metastases and ENE in HNSCC by means of
pretreatment CT images and three-dimensional deep learning
neural networks (22). In this study they trained the neural
network using a data set of 2,875 CT-segmented lymph node
specimens and achieved diagnostic results which exceeded those
of human clinicians (22). The area under the receiver operating
characteristics curve for diagnosing ENE and lymph node
metastases was 0.91 (95% CI = 0.85–0.97)—ENE of lymph node
metastases could be predicted with a sensitivity of 88% and
specificity of 85% (22). The diagnosis of ENE bymeans of CT was
additionally the subject of the recently published work by Faraji
et al. (15). Seventy-three patients with HPV-positive OPSCC
treated by primary surgery and neck dissection were reviewed
for the presence of seven defined criteria of CT imaging (15).
The pretreatment CT scans were evaluated by two radiologists
who were blinded to the pathologic ENE results (15). In the
evaluations, the presence of irregular nodal margins (highest
specificity of 94% for examiner A and 95% for examiner B) and
the absence of perinodal fatty tissue (highest sensitivity of 87%
for examiner A and 96% for examiner B) showed a significant
association with ENE (15).
In 2018 Hararah et al. published initial attempts at
pretreatment prediction of ENE and positive surgical margins
for OPSCC (23). In the course of analyzing prognostic
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FIGURE 1 | Microscopic view of lymph node metastases without ENE (A), with microscopic ENE (B) and with macroscopic ENE (C).
FIGURE 2 | Flow-chart of literature research adapted from PRISMA (24).
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parameters of 5,056 patients (3,336 HPV-positive), Hararah
et al. developed nomograms for the parameters ENE and/or
positive resection status for HPV-negative as well as HPV-
positive OPSCC (23). Regarding the prediction of postoperative
ENE, for HPV-positive tumors clinical ENE, cN staging, cT
staging, age, and tumor grading were integrated into the
nomogram as predictive parameters (AUC ROC = 0.66; p
< 0.01; 95% CI = 0.64–0.68) (23). Hararah et al. are thus
presenting additional approaches to diagnosing ENE which, as
a whole, could potentially facilitate clinical decision-making
regarding primary treatment. However, they particularly stress
the current aspiration to further develop clinical (and pathologic)
diagnostic methods.
Further studies and more prolonged use of the new TNM
classification are required to show how far the new clinical N
classification, or particularly the clinical diagnosis of ENE defined
therein, can succeed in everyday clinical practice and result in
reliable identification of ENE status or whether new diagnostic
methods will prevail in future. Understaging or upstaging of
patients not surgically treated should be avoided where the
prognostic influence of ENE is proven. Improving the modalities
for clinical diagnosis of ENE and standardizing ENE diagnosis
in general will thus continue to be the objective over the next
few years.
METHODS
The aim of this paper is to provide a structured overview of
current study results on the topic “Prognostic influence of ENE in
surgically treated HPV-positive OPSCC.” In order to investigate
a possible prognostic influence of ENE in HPV-positive
OPSCC, a literature research was conducted with PubMed.
Using the PubMed Search Builder the following search term
was created: ((((((((((extracapsular spread[Title/Abstract])
OR perinodal spread[Title/Abstract]) OR transcapsular
spread[Title/Abstract]) OR extranodal spread[Title/Abstract])
OR extracapsular extension[Title/Abstract]) OR
extranodal extension[Title/Abstract]) OR perinodal
extension[Title/Abstract]) OR transcapsular
extension[Title/Abstract])) AND (((hpv[Title/Abstract])
OR human papilloma virus[Title/Abstract]) OR
p16[Title/Abstract])) AND (((((head and neck squamous
cell carcinoma)) OR hnscc) OR oropharyngeal squamous
cell carcinoma) OR opscc). The process of literature research
is illustrated in Figure 2. 109 of 110 results were available
in English. The included studies were published before
July 2020.
Before screening the records, the following inclusion criteria
were defined: (a) OPSCC, (b) patient collective contains HPV-
positive tumors, (c) surgically treated collective/Neck Dissection
(with or without adjuvant therapy), (d) ENE-Status available,
(e) statement on the prognostic influence of ENE, (f) original
research paper. Full-text articles assessed for eligibility were
screened for further relevant publications. The publications
included in analysis were screened for their study results
referring to the prognostic impact of ENE in HPV-positive
OPSCC. The relevant results as well as characteristics of the
studies and number of cases are shown in Tables 1, 2 in
the following.
EXTRANODAL EXTENSION AS RISK AND
PROGNOSTIC FACTOR
Numerous studies in the past have shown that the presence
of ENE additionally worsens the prognosis of patients with
HNSCC (1, 8, 46–50). In a 2006 meta-analysis by Dunne et al.
involving 1,620 patients with diagnosed HNSCC and lymph node
metastasization, 5-year overall survival deteriorated to 30.7% in
the presence of ENE compared to 58.1% in the absence of ENE
(1, 50).
Furthermore, the correlation between ENE and locoregional
recurrence and distant metastases has been studied in recent
years. For example, Myers et al. showed in their publication
of 2001 on 266 patients with squamous cell carcinoma of the
tongue that ENE was the most significant prognostic parameter
for the risk of regional recurrence and distant metastases in their
population (1, 2). The meta-analysis by Mermod et al. from 2016
showed an odds ratio of 2.18 (95% CI = 1.23–3.87) for the
correlation between ENE and distant metastases (1).
In 2014 Künzel et al. analyzed, among other things, the
influence of ENE on the disease-specific survival of patients with
OPSCC not stratified to HPV status. The study analyzed 384
patients first diagnosed between 1980 and 2010 (48). One of
the findings was that ENE is associated with significantly worse
disease-specific survival of 50% compared to 81% in the absence
of ENE (p < 0.001) (48).
A few studies, however, demonstrated a lack of significant
worsening of outcome due to ENE in HPV-positive OPSCC
(1, 25, 27, 29, 30). In particular, the research group of Sinha et al.
investigated the influence of ENE in HPV-induced OPSCC in
detail (1, 25–27, 30, 31). In 2012, with regard to a group of 171
patients with p16-positive surgically treated OPSCC (adjuvant
RT: n = 73, adjuvant CRT: n = 69), they published a lack of
significant impact of ENE on overall and disease-specific survival
(1, 26). In their multivariate analysis from 2012 (27), ENE (except
for soft tissue deposits) did not prove prognostic in HPV-positive
OPSCC in a prospective transoral laser surgery database (n= 152
patients—adjuvant RT: n = 66, adjuvant CRT: n = 67) (1, 27).
In 2015 in their multivariate analysis of p16-positive OPSCC
treated by surgery and neck dissection (n = 220 patients—
RT: n = 97, CRT: n = 75), one of their findings was that the
number of lymph node metastases (≥5)—but not ENE—was an
independent prognostic factor (1, 30).
Their analyses of 2011, 2012, and 2015 additionally
investigated the significance of the extent of ENE and its
prognostic influence: Thus Lewis et al. also described a lack of
significant influence of ENE on overall survival, disease-free
survival (DFS), and disease-specific survival (DSS) in surgically
treated HPV-positive OPSCC (n = 101 patients–postoperative
radiation therapy: n= 100, postoperative chemotherapy: n= 44)
(25). In fact, a significant correlation was found between the
presence of soft tissue deposits (defined as grade 4 ENE) and
overall survival, DSS and DFS. Given a correlation with the
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TABLE 1 | Summary of the described studies on the prognostic influence of ENE in HPV-positive OPSCC—part 1.
References Characteristics Patients Prognostic influence of ENE in HPV+ OPSCC
Lewis et al. (25) − Monocentric
− Retrospective
− Surgical
n = 101 OPSCC
(HPV+: n = 90)
− Univariate analysis: only grade 4 ENE (soft tissue deposit)
associated with OS (p < 0.001), DFS (p = 0.0025), and DSS
(p = 0.0013) (but correlates with T stage)
− Multivariate analysis: no significant correlation with OS, DFS,
or DSS
Haughey et al. (26) − Monocentric
− Retrospective
− Surgical
n = 171 OPSCC
(HPV+)
ENE not significantly associated with OS, DSS, or DFS
Sinha et al. (27) − Monocentric
− Prospective
− Surgical
n = 152 OPSCC
(HPV+)
− Univariate analysis: grade 4 ENE (soft tissue deposit) significantly
associated with DFS (p = 0.02), DSS (p = 0.03), and OS
(p = 0.009)
− Multivariate analysis: grade 4 ENE (soft tissue deposit)
significantly associated with DFS (p = 0.01), DSS (p = 0.01),
and OS (p = 0.03)
− ENE grade 0–3 not prognostic





n = 139 OPSCC
(HPV+: n = 91)
n = 31 OSCC
(HPV+: n = 7)
ENE in univariate and multivariate analysis not significantly
associated with DSS




n = 133 OPSCC
(HPV+: n = 76)
n = 214 OSCC
− OPSCC: ENE not significantly associated with DSS (p = 0.936)
(also for HPV-OPSCC, p = 0.198)
− ENE as significant independent prognostic factor in OSCC
Sinha et al. (30) − Monocentric
− Prospective
− Surgical
n = 220 OPSCC
(HPV+)
− ENE not prognostic for DFS, DSS, or recurrence
− Number of lymph node metastases significantly associated
with outcome
Sinha et al. (31) − Monocentric
− Prospective
− Surgical
n = 222 OPSCC
(HPV+)
− Grade 4 ENE (soft tissue deposit) significantly associated with
distant metastases and DMFS (p= 0.004) only for T3–T4 tumors
− No significant correlation with regional recurrence
Iyer et al. (32) − Monocentric
− Retrospective
− Surgical
n = 201 OPSCC
(HPV+: n = 106)
ENE not significantly associated with 5Y-OS (p = 0.300),
5Y-DSS (p = 0.116), or 5Y-RFS (p = 0.753)
Kaczmaret al. (33) − (Monocentric)
− Retrospective
− Surgical
n = 114 OPSCC
(HPV+)
Univariate analysis: ENE not significantly associated with
increased risk of local and distant progression (p = 0.575,
p = 0.793)
Kumar et al. (34) − Monocentric
− Retrospective
− Surgical
n = 289 OPSCC
(HPV+: n=172)
− Univariate analysis: ENE nearly reached significance (p= 0.0553)









n = 62 OPSCC
(HPV+: n = 36)
n = 21 CUP
(HPV+: n = 9)
− ENE not significantly associated with RFS (p = 0.93) or DSS (p
= 0.91)
Tassone et al. (36) − Monocentric
− Retrospective
− Surgical
n = 85 OPSCC
(HPV+)
− Logistic regression analysis of recurrence (as binary variable):
ENE not significantly associated with recurrence (OR = 2.28,
p = 0.383)
− Univariate analysis of DFS: ENE no significant impact on DFS (p
= 0.25)
CUP, cancer of unknown primary; DFS, disease-free survival; DMFS, distant metastasis-free survival; DSS, disease-specific survival; ENE, extranodal extension; HPV, human
papillomavirus; HR, hazard ratio; NCDB, National Cancer Database; OPSCC, oropharyngeal squamous cell carcinoma; OR, odds ratio; OS, overall survival; OSCC, oral squamous
cell carcinoma; RFS, recurrence-free survival.
T stage, it was not confirmed in the multivariate analysis
(25). In their 2012 publication, Sinha et al. then confirmed a
significant influence of soft tissue deposits on overall survival,
DFS and DSS (27). In 2015 they again published results
which showed a significant correlation between soft tissue
deposits and distant metastasis-free survival for T3–T4 tumors
only (n = 222 patients, adjuvant RT: n = 97, adjuvant CRT:
n= 78) (31).
In this connection Maxwell et al. reached the following
conclusion in their 2013 publication (29): In their analysis of 133
patients with OPSCC and 214 patients with carcinoma of the oral
cavity (surgically treated in the years 1983–2009), they found no
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TABLE 2 | Summary of the described studies on the prognostic influence of ENE in HPV-positive OPSCC—part 2.
References Characteristics Patients Prognostic influence of ENE in HPV+ OPSCC




n = 1,043 OPSCC
(HPV+)
− Univariate analysis: significant correlation with 3Y-OS (p = 0.01)
− Multivariate analysis: significant correlation with OS (HR = 1.89; 95%
CI = 1.01–3.51; p = 0.046)
− Only patients with 1 lymph node metastasis: significant correlation with
3Y-OS (p = 0.033)





n = 3,745 OPSCC
(HPV+)
− Univariate analysis: significant correlation with 4Y-OS (p < 0.001)
− Also after stratification according to N classification for pN1 tumors




n = 75 OPSCC
(HPV+)
− Univariate analysis: significant correlation with 5Y-DC rate (p = 0.046) and
5Y-PFS (p = 0.021)
− Multivariate analysis: independently prognostic of worse DC (HR = 8.26;
95% CI = 1.24–55.21; p = 0.029) and PFS (HR = 4.64; 95% CI = 1.18–
18.29; p = 0.028)
− No significant difference in 5Y-LRC or OS
Meyer et al. (40) − Monocentric
− Retrospective
− Surgical
n = 88 OPSCC
(HPV+: n = 39)
− Univariate analysis: significant correlation with OS (p = 0.012) und RFS
(p = 0.012)
− Multivariate analysis: ENE not included




n = 4,153 OPSCC
(HPV+)
− Univariate analysis: significant correlation with 5Y-OS (p = 0 < 0.001)
− Stratified according to N stage (8th edition): significant correlation with
5Y-OS (p = 0 < 0.001)
− Multivariate analysis: significant prognostic parameter (HR = 1.90; 95%
CI = 1.35–2.67; p = 0 < 0.001)




n = 3,407 OPSCC
(HPV+)
− Univariate analysis: significant correlation with OS (HR = 2.04; 95%
CI = 1.59–2.63; p < 0.001)
− Multivariate analysis: significant correlation with OS (HR = 1.66; 95%
CI = 1.26–2.19; p < 0.001)
Beltz et al. (42) − Monocentric
− Retrospective
− Surgical
n = 95 OPSCC
(HPV+: n = 50)
− Univariate analysis: significant correlation with 5Y-OS, (p = 0.008)




n = 736 OPSCC
(HPV+)
− Univariate analysis: presence of microscopic ENE (p = 0.009) or
macroscopic ENE (p = 0.007) associated with increased risk of death
− Multivariate analysis: macroscopic ENE vs. non-ENE as independent risk
factor for death (HR = 4.9; 95% CI = 1.4–18.1; p = 0.016)
Freitag et. al. (44) − Monocentric
− Retrospective
− Surgical
n = 92 OPSCC
(HPV+)
− p16+: significant correlation with OS (p = 0.007) and TSS (p = 0.047)
− p16+/HPV16 DNA+: significant correlation with OS (p = 0.013) and TSS
(p = 0.026)
− Multivariate analysis: independent predictor for decreased OS
(p = 0.033), TSS (p = 0.165), PFS (p = 0.42), and DFS (p = 0.04)






(HPV+: n = 8,780)
− Pathologic and clinical ENE associated with decreased survival
− No significant difference between pathologic and clinical ENE
CI, confidence interval; DC, distant control DFS, disease-free survival; ENE, extranodal extension; HPV, human papillomavirus; HR, hazard ratio; NCDB, National Cancer Database;
OPSCC, oropharyngeal squamous cell carcinoma; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; TSS, tumor-specific survival.
significant association between ENE status and DSS for HPV-
positive and HPV-negative patients (OPSCC: adjuvant radiation:
n= 111, adjuvant chemotherapy: n= 40).
The investigation of potential prognostic parameters of HPV-
positive and HPV-negative OPSCC and oral carcinomas of
170 patients (OPSCC: n = 139, 65.5% HPV-positive) was also
the purpose of the study by Klozar et al. published in 2013
(28). For HPV-negative tumors, univariate analysis showed
UICC stage, Pt, and pN classification, number of positive
lymph nodes and ENE to be significant prognostic parameters.
Except for ENE, these were confirmed in the multivariate
analysis. For HPV-positive tumors, by contrast, none of these
parameters showed a significant correlation with the DSS of
patients (28).
In 2015 Iyer et al. published the following results: While ENE,
resection status, lymph vessel invasion, and pN category were
independent predictors of survival in the case of HPV-negative
OPSCC, they were not prognostic for HPV-positive tumors
[in respect of recurrence-free survival (RFS), DSS, and OS]
(n= 201 patients, adjuvant RT: n= 138) (32). In addition to that,
Kumar et al. (34) showed that ENE (p = 0.0021) and advanced
T-classification represent significant predictors of survival in
Frontiers in Oncology | www.frontiersin.org 6 August 2020 | Volume 10 | Article 1394
Beltz et al. Extranodal Extension in HPV-OPSCC
HPV-negative surgically treated OPSCC (most patients treated
with adjuvant RT/RCT based on NCCN guidelines). While ENE
nearly reached significance in the univariate analysis of HPV-
positive OPSCC (p = 0.0553), multivariate analysis revealed that
ENE was not significantly associated with survival (p = 0.7644)
(34). Kharytaniuk et al. in their 2016 analysis of 83 patients
(n = 62 with OPSCC, n = 21 with cancer of unknown
primary = CUP) with neck dissection as part of primary
definitive treatment—also confirmed that ENE is not a negative
prognostic factor for HPV-positive OPSCC (in respect of RFS
and DSS) (35) (surgery only: n = 8, RT: n = 50, CRT: n = 25).
Kaczmar et al. showed that ENE does not correlate with increased
risk of local as well as distant progression in HPV-positive
OPSCC (114 surgical patients, 89 with adjuvant radiation, 54 with
adjuvant chemotherapy) in univariate analysis (33). In addition
to that, Tassone et al. confirmed that ENE is not significantly
associated with recurrence and DFS in a retrospective analysis
of 85 surgically treated HPV-positive OPSCC (adjuvant RT:
n = 81, adjuvant systemic therapy: n = 52) (36). Table 1
summarizes the studies described in this chapter showing no or
weak prognostic influence of ENE in primarily surgically treated
HPV-positive OPSCC.
EXTRANODAL EXTENSION IN THE
CONTEXT OF THE 8TH UICC
CLASSIFICATION
According to the 8th edition of the TNM classification, the
presence of ENE leads to distinct upstaging solely in HPV-
negative OPSCC. For HPV-positive tumors, only the number
of positive lymph nodes is decisive in terms of pTNM staging.
This is why the prognostic influence of ENE in HPV-induced
tumors is currently the focus of a number of studies. In a 2019
study by the present authors, the application and prognostic
impact of the new TNM classification as well as the factors
HPV status and ENE were examined in a group of 255 patients
with OPSCC first diagnosed in the years 2008–2015 (42). This
included analyzing the overall survival of HPV-positive patients
with negative vs. positive ENE status treated with surgery alone
or surgery combined with adjuvant radiation/chemoradiation.
In this cohort adjuvant therapy was standard in case of
pathologically proven ENE. This study addressed, among other
things, the question of whether ENE can actually be ignored
in HPV-mediated OPSCC (42). Ninety five patients met the
inclusion criteria for ENE analysis. The Kaplan-Meier curves
presented (Figure 3) and the log rank test revealed a statistically
significant deterioration of overall survival in the presence of
ENE for HPV-positive patients in the univariate analysis (ENE-
negative: OS= 92.9%, ENE-positive: 68.0%, p= 0.008) (42).
The univariate analysis of the study byMeyer et al. (40), which
examined the prognostic influence of the lymph node ratio, also
showed a significant influence of ENE on overall survival of
HPV-positive patients with surgically treated OPSCC (p= 0.012;
ENE not included in the multivariate analysis) (surgery: n = 21,
surgery+ R(C)T: n= 67).
FIGURE 3 | Prognostic influence of extranodal extension in patients with
p16-positive oropharyngeal carcinoma (ENE, extranodal extension) (42).
In 2017 Zhan et al. published results of their validation of
the new staging system based on 3,745 cases of HPV-positive
OPSCC treated by surgery and neck dissection from the National
Cancer Database (NCDB) for the years 2010–2014 (surgery only:
n = 642, surgery + RT: n = 1,005, surgery + CRT: n = 1,773)
(38). As well as a general evaluation of the new staging algorithm,
the study focused on analyzing the prognostic influence of ENE
in HPV-positive OPSCC. During the course of their analyses,
Zhan et al. demonstrated a statistically significant influence of
ENE on 4-year overall survival in HPV-positive OPSCC (ENE-
negative: 92% vs. ENE-positive: 85%, p < 0.001) (38). Upon
stratification according to pN classification, ENE proved to be a
significant prognostic parameter for the 4-year overall survival
of HPV-positive patients with pN1 stage [pN1: ENE-negative
92%, ENE-positive 87% (p = 0.004); pN2: ENE-negative 88%,
ENE-positive 77% (p= 0.061)] (38).
The described results are consistent with the results of
analyses by An et al. published in 2017 (37): In their study
the prognostic value of ENE was examined in a group of
1,043 patients with HPV-positive OPSCC (pT1–T4, pN1–N3,
M0, R0) who underwent primary surgical treatment (adjuvant
RT: n = 306, adjuvant CRT: n = 498). Patients who met the
defined inclusion criteria were identified via the NCDB for
the years 2010–2012 (37). In the course of their analyses An
et al. demonstrated that a positive ENE status is associated with
a significant deterioration of overall survival of HPV-positive
patients (3-year overall survival: 89.3 vs. 93.6%, p = 0.01) (37).
No significant difference in overall survival was found between
cases with microscopic vs. macroscopic ENE (37). Furthermore,
An et al. also demonstrated in themultivariate analysis that rather
than the presence of ≥5 lymph node metastases—as integrated
into the TNM classification for HPV-positive OPSCC—it is
the presence of ENE that is significantly associated with a
deterioration of overall survival (HR= 1.89; 95% CI= 1.01–3.51;
p = 0.046) (37). Hence the results to some extent contradict the
current system of N classification of p16-positive OPSCC (42).
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For HPV-positive OPSCC patients who have undergone primary
surgical treatment, it is only the absolute number of lymph
nodes involved (cut-off between pN1 and pN2: ≥5 involved
lymph nodes) which has the decisive prognostic influence on
determining the pN category according to the 8th edition (42).
Given comparable hazard ratios (≥5 lymph node metastases:
HR = 1.81, p = 0.086 vs. ENE: HR = 1.89, p = 0.046), An
et al. do not question the cut-off of ≥5 lymph node metastases
as a prognostic parameter for HPV-positive OPSCC. However,
they do advocate evaluation of both parameters as potential
prognostic factors—especially since a higher number of lymph
node metastases is associated with the presence of ENE with a
greater probability (37).
In order to eliminate the possible confounding variable of
“total number of lymph node metastases” from the analysis and
to investigate the relationship between ENE and overall survival
in isolation, overall survival was analyzed only in patients with
one lymph node metastasis: once again a deterioration of 3-year
overall survival to 90.8% compared to 96.0% (p = 0.033) was
observed (37).
In addition to that, Shevach et al. (39) published results
showing that ENE-positive status is significantly associated
with a deterioration of distant control and progression-free
survival in univariate and multivariate analysis (39). They
evaluated a collective of 75 patients with HPV-mediated OPSCC
treated with surgery, respectively, neck dissection followed by
adjuvant radiotherapy/chemoradiotherapy. However, there was
no significant difference in OS and locoregional control between
ENE-negative and -positive patients (39).
Bauer et al. recently showed that ENE represents a
significant prognostic parameter in respect of overall survival
in HPV-mediated OPSCC (5). In their paper published
in 2019, they analyzed the prognostic significance of ENE
in a group of 4,153 patients with HPV-positive OPSCC
from the NCDB who were treated surgically and by neck
dissection (N0 = 531, ENE-positive: 1,429, ENE-negative:
2,193—surgery only: n = 923, surgery/radiation: n = 1,403,
surgery/radiation/chemo: n = 1,827) (5). The univariate analysis
revealed a statistically significant correlation between ENE and
overall survival in HPV-positive patients (p < 0.001) with 5-year
overall survival of 92.6% (95% CI = 90.5–94.7%) for negative
ENE status compared to 84.0% (95% CI= 80.7–87.4%) for ENE-
positive tumors (5). Furthermore, when stratified according to N
stage (8th edition), tumors classified as N1/ENE-negative showed
the highest 5-year overall survival rate of 93.4% (95% CI= 91.3–
95.5%), whereas N2/ENE-negative and N1/ENE-positive tumors
had similar 5-year overall survival of 87.8 and 87.3%, respectively,
(5). The multivariate analysis (with age, gender, population
group, morbidity, T stage, treatment, and resection status as
possible confounding variables) revealed in respect of mortality
risk a hazard ratio of 1.90 (95% CI = 1.35–2.67) in the presence
of ENE vs. ENE-negative OPSCC (p < 0.001). The pathologic
N stage—or hence the number of positive lymph nodes—was
significantly associated with patients’ outcome (pN2 vs. pN1:
HR = 1.53) (5). Furthermore, Bauer et al. demonstrated that—
when combining pN category and ENE status—tumors classified
as N2/ENE-positive had the lowest 5-year overall survival rate
(HR= 2.93; 95% CI= 1.94–4.43; p < 0.001) in comparison with
N1/ENE-negative OPSCC (HR = 1.00) (5). OPSCC classified as
N1/ENE-positive also showed nearly twice as high mortality risk
(HR = 1.88; 95% CI = 1.26–2.80; p = 0.002) as ENE-negative
pN1 tumors. Bauer et al. thus concluded in the course of their
evaluation that ENE is prognostic irrespective of the number of
positive lymph nodes and that the combination of ENE status
and number of positive lymph nodes (pN category) particularly
leads to an improved picture of mortality risk (5). All in all, the
work by Bauer et al. including 4,153 patients represents a large
study in this field for HPV-positive OPSCC and—as a result of
the length of follow-up—also allows the prognostic influence of
ENE on 5-year overall survival to be evaluated. As Bauer et al.
also stress, this is particularly significant in view of the relatively
good prognosis of HPV-positive tumors. Furthermore, a large
number of possible confounding variables were integrated into
the multivariate analysis. In summary, the large number of cases
included and the length of follow-up made it possible for the
results to reach statistical significance (5).
Furthermore, Miccio et al. recently published their study on
the influence of contralateral lymph node metastasization and
ENE on survival in HPV-mediated OPSCC (41). Three thousand
four hundred seven patients from the NCDB (2010–2015) with
surgically treated, HPV-positive OPSCC and a minimum of 10
lymph nodes removed made up the study population (adjuvant
RT: n= 1,262, adjuvant CRT: n= 1,501, unknown: n= 78) (41).
In their evaluation, the research group of Miccio et al. concluded
that, in both the univariate analysis (HR = 2.04; 95% CI = 1.59–
2.63; p < 0.001) and the multivariate analysis (HR = 1.66; 95%
CI = 1.26–02.19; p < 0.001), the presence of ENE is associated
statistically highly significantly with a deterioration of overall
survival in HPV-positive tumors and it should be included in
future staging algorithms (41).
In 2019, Han et al. published a retrospective analysis of 736
patients with only surgically treated HPV-positive OPSCC from
the NCDB (2010–2014) (43). Among other things, they showed
that microscopic or macroscopic ENE results in a significantly
worse OS when compared to positive lymph nodes without
ENE (5J-OS: 91% vs. 78%; p < 0.0001) (43). In addition,
Freitag et al. recently published their analysis of a cohort
of 92 patients with surgically treated HPV-mediated OPSCC
(IC+OP+RT: n = 8, OP: n = 21, OP+RT: n = 23, OP+RCT:
n = 39, OP+RT+Cetuximab: n = 1) (44). Their multivariate
analysis showed that ENE represents an independent predictor
for decreased OS (p= 0.033), tumor-specific survival (p= 0.165),
progression-free survival (p = 0.42), and DFS (p = 0.04)
(44). The results of their investigation as a whole led them
to the conclusion that ENE (as well as HPV16 DNA status)
should be integrated in the prognostic staging algorithm of
HPV-mediated OPSCC (44). Furthermore, Gal et al. recently
showed a decreased survival in the presence of clinical and
pathological ENE compared to the absence of ENE. Their
retrospective SEER database study analyzed 16,845 primarily
surgical treated patients with tonsillar and base of the tongue
primaries (45).
As a whole the results described above contrast with the
conclusions of the 2016 review by Mermod et al. which included
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an analysis of the prognostic significance of histopathologically
proven ENE in HPV-positive OPSCC (1). Individual results of
the studies included have already been presented: overall, the
analyses had shown a lack of negative influence of ENE in HPV-
positive OPSCC (1). Compared with the monocentric design of
the studies analyzed by Mermod et al. (1) and the maximum
number of 222 patients included Sinha et al. the great strengths
of the studies by Zhan et al. (38), An et al. (37), Bauer et al. (5),
Miccio et al. (41), andGal et al. (45) are the case numbers of 3,745,
1,043, 4,153, 3,407, and 16,845 patients, respectively, and hence
their power as well as their multicenter design.
Table 2 summarizes the described studies showing significant
influence on prognosis of ENE in HPV-positive OPSCC.
The possible influence of tobacco consumption of patients
was not analyzed because of the lack of recording in the
NCDB. The influence of nicotine consumption on the risk and
prognostic profile of HPV-positive OPSCC, however, is a relevant
parameter according to the results of Ang et al. (51) and should
be considered in future prospective analyses. Kompelli et al.
recently published an analysis of patients with HPV-related
OPSCC (52): Aim of this study was to investigate the impact of
pathologic prognostic factors in the context of chronic tobacco
use. The results show that, among other things, presence of
ENE did not significantly affect survival in HPV-positive heavy
smokers (≥20 pack years) (52). However, HPV-positive ENE-
positive heavy smokers had a significant decrease in survival
(similar to HPV-negative patients) compared to HPV-positive
non-smokers with positive ENE-status (52). In the future, the
prognostic impact of ENE should also be evaluated in the context
of tobacco consumption and the prognostic influence of tobacco
abuse in HPV-positive OPSCC should be examined in detail
further on.
All in all, the current study results from various publications
presented here emphasize that ENE is a risk and prognostic
factor, including HPV-positive OPSCC, which to date has
not been integrated into the staging algorithm of the TNM
classification. Possible reasons for the different results of the
studies mentioned are discussed by Bauer et al. (5), An et al.
(37), and Zhan et al. (38). For example, the excellent prognosis
of HPV-positive OPSCC could lead to the fact that only studies
with a higher number of cases can reveal statistically significant
differences between ENE-positive and—negative tumors (5). An
et al. stress the greater power achieved by larger patient collectives
as well (37). In addition, Zhan et al. support this argumentation
with their data–with a moderate effect size on OS (5–11% on 4Y-
OS), significant results are only likely in high numbers of cases
(38), such as those made possible by the NCDB. Nonetheless, the
prognostic influence of ENE in surgically treated HPV-positive
OPSCC remains a topic that should be analyzed in further
(prospective) multicenter studies.
Limitations of this work are that only studies that explicitly
examined ENE in HPV-positive OPSCC (e.g., ENE terms in
title/abstract) were included—therefore other possibly relevant
research results, which were not identified through literature
research or references, could have been missed. The aim of this
publication was to provide the reader with an overview of the
current status of research in this field in a structured form.
Due to a limited number of studies that explicitly focus on this
issue, as well as partly limited comparability, we did not choose
a systematic review, but a structured review according to the
PRISMA guidelines. We performed our literature research as
structured and traceable as possible. Furthermore, no quality
assessment of the included studies was carried out. Despite the
focus on surgically treated collectives, it can be assumed that
the therapy algorithms (especially regarding adjuvant therapy)
vary to a certain extent from institute to institute, which
influences the comparability of the studies. As histopathologically
proven ENE is an accepted risk factor in HNSCC in general
and de-escalation strategies in HPV-positive tumors have not
been integrated into clinical practice, the majority of patients
of all discussed studies should have been treated by adjuvant
radiotherapy. As a topic that is currently gaining more
and more interest, a future meta-analysis—including possible
additional publications of the next months/years—should
be considered.
CONCLUSION
Whether the prognostic influence of ENE of lymph node
metastases can actually be ignored for HPV-positive tumors
in the TNM classification system should be reevaluated
in detail in the context of prospective multicenter studies.
According to the study results presented here, it also seems
necessary to record ENE in the tumor documentation for HPV-
positive tumors. Furthermore, it is also the extent of ENE
(macroscopic vs. microscopic—ENE ≤/>1mm, respectively,
ENE ≤/>2mm) that should be examined and documented
as it represents an additional prognostic factor. The methods
applied (including ultrasound, CT, MRI) in the clinical
diagnosing of ENE have limited sensitivity and specificity.
In this regard initial attempts at computer-aided analysis
of image data should be pursued. Furthermore, clinical
diagnostic criteria should be standardized overall at the
international level.
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